PTO/SB/08a (01-09)
Approved for use through 02/28/2009. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known	
Application Number	09/414,384
Filing Date	10/07/1999
First Named Inventor	Andrew CLARK
Art Unit	3771
Examiner Name	Dixon, Annette Fredericka
Attorney Docket Number	53325-US-CNT (0037.00)

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 6182655	02-06-2001	Keller et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
		WO 97/20589	06-12-1997	Jago Pharma AG	equivalent US6182655	

Examiner Signature	/Annette Dixon/ (11/27/2012)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.D./ (11/27/2012)

PTO/SB/08b (01-09)
Approved for use through 02/28/2009. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 3

Complete if Known	
Application Number	09/414,384
Filing Date	10/07/1999
First Named Inventor	Andrew CLARK
Art Unit	3771
Examiner Name	Dixon, Annette Fredericka
Attorney Docket Number	53325-US-CNT (0037.00)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	AA	BARROWCLIFFE et al., "The In-Vitro Evaluation of a Novel Multi-Dose Dry Powder", The Aerosol Society, 1996; pp. 82-85.	
	BB	CHRYSTYN, "The Diskus Inhaler, A Review of its Pharmaceutical and Clinical Performance", Clinical Drug Investigations, 1999; pp. 287-296, Vol. 18, No. 4	
	CC	CONWAY et al., "Comparison of Peak Pressure Drops Through Powder Inhalers During Inspiration at Maximum Flow Rate", 1996; pp. 153, A59.	
	DD	MALTON et al., "A Comparison of In-Vitro Drug Delivery from Salbutamol Diskus and Terbutaline Turbohaler Inhalers", J. Pharm., Med., 1996; pp. 35-48, Vol. 6.	
	EE	MALTON et al., "A Comparison of In-Vitro Drug Delivery from Two Multidose Powder Inhalation Devices", Euro. J. Clinical Research, 1995; pp.177-193, Vol. 7.	
	FF	NEWHOUSE et al., "Clickhaler (a novel Dry Powder Inhaler) Provides Similar Bronchodilation to Pressurized Metered-Dose Inhaler, Even at Low Flow Rates", Clinical Investigation 199~~0~~; pp. 952-956. 1999 /ad/	
	GG	PRIME et al., "The Flixotide Diskus, a New Multi Dose Powder Inhaler -- In-Vitro Evaluation Using an Inhalation Simulator", J. Aerosol Med., 1995; pp. P137.	

Examiner Signature	/Annette Dixon/ (11/27/2012)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.D./ (11/27/2012)

PTO/SB/08b (01-09)
Approved for use through 02/28/2009. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 3

Complete if Known	
Application Number	09/414,384
Filing Date	10/07/1999
First Named Inventor	Andrew CLARK
Art Unit	3771
Examiner Name	Dixon, Annette Fredericka
Attorney Docket Number	53325-US-CNT (0037.00)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	E	CLARK et al., "The Relationship Between Powder Inhaler Resistance and Peak Inspiratory Conditions in Healthy Volunteers -- Implications for In Vitro Testing", Journal of Aerosol Medicine, 1993; pp. 99-110, Vol. 6 No. 2.	
	F	HILL, "Characteristics of an Active, Multiple Dose Dry Powder Inhaler", Respiratory Drug Delivery IV, 1994; pp. 109-116.	
	G	DOLOVICH, "Physical Principles Underlying Aerosol Therapy", Journal of Aerosol Medicine, 1989; pp. 171-186, Vol. 2 No. 2.	
	H	CLARK, "Effect of Powder Inhaler Resistance Upon Inspiratory Profiles in Health and Disease", Respiratory Drug Delivery IV, 1994; pp. 117-123.	
	I	ROSS et al., "Effect of Inhalation Flow Rate on the Dosing Characteristics of Dry Powder Inhaler (DPI) and Metered Dose Inhaler (MDI) Products", Journal of Aerosol Medicine, 1996; pp. 215-226, Vol. 9 No.2.	
	J	Lawford et al., "Pressurized Aerosol Inhaler Techniques: How Important are Inhalation from Residual Volume, Inspiratory Flow Rate and the Time Interval Between Puffs?", J. Dis. Chest, 1983; 77, pp. 276-281.	

Examiner Signature	/Annette Dixon/ (11/27/2012)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.D./ (11/27/2012)